Sorrento Therapeutics, Inc, a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone858-203-4100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.19 million
Profitability
Miscellaneous
Employees382
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions
What is Sorrento Therapeutics' stock symbol?
Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."
How were Sorrento Therapeutics' earnings last quarter?
Sorrento Therapeutics Inc (NASDAQ:SRNE) announced its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.01. The biopharmaceutical company had revenue of $6.48 million for the quarter, compared to the consensus estimate of $7.50 million. Sorrento Therapeutics had a negative return on equity of 136.52% and a negative net margin of 1,107.37%. View Sorrento Therapeutics' Earnings History.
When is Sorrento Therapeutics' next earnings date?
What price target have analysts set for SRNE?
4 Wall Street analysts have issued 1 year price targets for Sorrento Therapeutics' stock. Their predictions range from $10.00 to $30.00. On average, they anticipate Sorrento Therapeutics' share price to reach $18.25 in the next twelve months. This suggests a possible upside of 1,062.4% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics.
What is the consensus analysts' recommendation for Sorrento Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics.
What are Wall Street analysts saying about Sorrento Therapeutics stock?
Here are some recent quotes from research analysts about Sorrento Therapeutics stock:
- 1. According to Zacks Investment Research, "Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and infectious disease. Sorrento Therapeutics, Inc. is based in San Diego, California. " (10/8/2019)
- 2. HC Wainwright analysts commented, "We ascribe a value of $5.5B based on a sum- of-the-parts approach, or a price per share of $30.00, assuming 183M projected fully-diluted shares outstanding as of mid-2020." (8/12/2019)
Has Sorrento Therapeutics been receiving favorable news coverage?
News articles about SRNE stock have trended negative on Monday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sorrento Therapeutics earned a daily sentiment score of -2.6 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Sorrento Therapeutics.
Are investors shorting Sorrento Therapeutics?
Sorrento Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 12,630,000 shares, an increase of 10.1% from the August 30th total of 11,470,000 shares. Based on an average trading volume of 1,110,000 shares, the days-to-cover ratio is presently 11.4 days. Currently, 13.3% of the company's shares are sold short. View Sorrento Therapeutics' Current Options Chain.
Who are some of Sorrento Therapeutics' key competitors?
Some companies that are related to Sorrento Therapeutics include Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), Bioanalytical Systems (BASI), HedgePath Pharmaceuticals (HPPI), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX), Vitality Biopharma (VBIO), US Stem Cell (USRM), Protalex (PRTX) and Geovax Labs (GOVX).
What other stocks do shareholders of Sorrento Therapeutics own?
Who are Sorrento Therapeutics' key executives?
Sorrento Therapeutics' management team includes the folowing people:
- Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 55)
- Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 69)
- Mr. George K. Ng, Corp. Sec. (Age 45)
- Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 51)
- Ms. Deborah H. Telman, Sr. VP & Gen. Counsel
How do I buy shares of Sorrento Therapeutics?
Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Sorrento Therapeutics' stock price today?
One share of SRNE stock can currently be purchased for approximately $1.57.
How big of a company is Sorrento Therapeutics?
Sorrento Therapeutics has a market capitalization of $205.64 million and generates $21.19 million in revenue each year. The biopharmaceutical company earns $-203,540,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe.View Additional Information About Sorrento Therapeutics.
What is Sorrento Therapeutics' official website?
How can I contact Sorrento Therapeutics?
Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]
MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
